Topic: Applications in health: human insulin, vaccines, gene therapy· Biotechnology and Its Applications

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because :

1. Genetically engineered lymphocytes are not immortal cells.

2. Retroviral vector is introduced into these lymphocytes.

3. Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages

4. Lymphocytes from patient's blood are grown in culture, outside the body.

Doubtly Asked 30 Oct 2026 NEET UG 2022 Practice test neet Save WhatsApp Report

1 answer

Best answer

Answer: 1. Genetically engineered lymphocytes are not immortal cells.

Key idea: Lymphocytes are short-lived, so the gene-corrected cells must be given again and again.

In ADA-deficiency therapy, the patient's lymphocytes are grown in culture, a functional ADA gene is introduced using a retroviral vector, and the cells are returned. But these lymphocytes are not immortal, so the patient needs periodic infusions. A permanent cure would need the gene to be put into marrow cells at an early embryonic stage.

Doubtly AI · 30 Oct 2026 AI-generated · not yet verified Report

Was this answer helpful?

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because :

1 answer

Your answer